Razoxane: a review of 6 years' therapy in psoriasis

Publisher Website
Google Scholar
Abstract
Razoxane is an effective drug in the systemic treatment of psoriasis with an initial response rate of 97%. After continuous therapy for up to 6 yr, 72% of patients remained on the drug with a good therapeutic benefit. It is useful in all forms of cutaneous psoriasis and psoriatic arthropathy. It does not appear to produce hepatic damage and is particularly useful in patients intolerant of methotrexate. It was used as drug of 1st choice in the systemic treatment of psoriasis, but several well-recognized side effects make careful follow-up necessary; 18% of patients stopped razoxane because of these side effects. However, razoxane has a valuable place in the systemic treatment of severe psoriasis.